Trial reportBMJ quality & safety2020
'New Medicine Service': supporting adherence in people starting a new medication for a long-term condition: 26-week follow-up of a pragmatic randomised controlled trial.
Trial report in BMJ quality & safety, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01635361 (Understanding and Appraising the New Medicine Service in England), which is not on this map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Understanding and Appraising the New Medicine Service in England
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Consultation-based interventions to optimize medication adherence in primary care: a systematic review.Family practice · 2026Pooled it
- Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).The Cochrane database of systematic reviews · 2021Pooled it
- Prevalence and Nature of Medication Errors and Medication-Related Harm Following Discharge from Hospital to Community Settings: A Systematic Review.Drug safety · 2020Pooled it
- A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation.Health technology assessment (Winchester, England) · 2024Trial
- Effectiveness of a medication adherence management intervention in a community pharmacy setting: a cluster randomised controlled trial.BMJ quality & safety · 2022Trial
- Adherence at 2 years with distribution of essential medicines at no charge: The CLEAN Meds randomized clinical trial.PLoS medicine · 2021Trial
- Adherence to triple-component antihypertensive regimens is higher with single-pill than equivalent two-pill regimens: A randomized controlled trial.Clinical and translational science · 2021Trial
- Improved persistence to statin therapy through a patient counseling intervention in community pharmacies - A nationwide cohort study.Exploratory research in clinical and social pharmacy · 2026Article
- Review
- A comprehensive global review on pharmacist-led strategies to support medication therapy in hypertensive patients.Journal of human hypertension · 2025Review
- [Pharmaceutical interventions in the new medicine service].Farmaceuticos comunitarios · 2025Observational
- Adoption of clinical pharmacist roles in primary care: longitudinal evidence from English general practice.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- Healthcare provider interventions to support medication adherence: state-of-the-science overview.Frontiers in pharmacology · 2025Review
- Association Between Receiving Medication Information and Adherence to Antihypertensive Medication: Findings from the 2023 Indonesian Health Survey.Patient preference and adherence · 2025Article
- Improving medication adherence in cardiovascular disease.Nature reviews. Cardiology · 2024Review
- An evaluation of written materials for supporting hypertensive patient education and counselling when performing a new medicine service in Poland.BMC medical education · 2024Article
- What affected UK adults' adherence to medicines during the COVID-19 pandemic? Cross-sectional survey in a representative sample of people with long-term conditions.Zeitschrift fur Gesundheitswissenschaften = Journal of public health · 2023Article
- Two-way Automated Text Messaging Support From Community Pharmacies for Medication Taking in Multiple Long-term Conditions: Human-Centered Design With Nominal Group Technique Development Study.JMIR formative research · 2022Article
- Recommendations for community pharmacy to improve access to medication advice for people from ethnic minority communities: A qualitative person-centred codesign study.Health expectations : an international journal of public participation in health care and health policy · 2022Article
- A qualitative exploration of the barriers and facilitators affecting ethnic minority patient groups when accessing medicine review services: Perspectives of healthcare professionals.Health expectations : an international journal of public participation in health care and health policy · 2022Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the effectiveness and cost-effectiveness of the community pharmacy New Medicine Service (NMS) at 26 weeks.
methodsPragmatic patient-level parallel randomised controlled trial in 46 English community pharmacies. 504 participants aged ≥14, identified in the pharmacy when presenting a prescription for a new medicine for predefined long-term conditions, randomised to receive NMS (n=251) or normal practice (n=253) (NMS intervention: 2 consultations 1 and 2 weeks after prescription presentation). Adherence assessed through patient self-report at 26-week follow-up. Intention-to-treat analysis employed. National Health Service (NHS) costs calculated. Disease-specific Markov models estimating impact of non-adherence combined with clinical trial data to calculate costs per extra quality-adjusted life-year (QALY; NHS England perspective).
resultsUnadjusted analysis: of 327 patients still taking the initial medicine, 97/170 (57.1%) and 103/157 (65.6%) (p=0.113) patients were adherent in normal practice and NMS arms, respectively. Adjusted intention-to-treat analysis: adherence OR 1.50 (95% CI 0.93 to 2.44, p=0.095), in favour of NMS. There was a non-significant reduction in 26-week NHS costs for NMS: -£104 (95% CI -£37 to £257, p=0.168) per patient. NMS generated a mean of 0.04 (95% CI -0.01 to 0.13) more QALYs per patient, with mean reduction in lifetime cost of -£113.9 (-1159.4, 683.7). The incremental cost-effectiveness ratio was -£2758/QALY (2.5% and 97.5%: -38 739.5, 34 024.2. NMS has an 89% probability of cost-effectiveness at a willingness to pay of £20 000 per QALY.
conclusionsAt 26-week follow-up, NMS was unable to demonstrate a statistically significant increase in adherence or reduction in NHS costs, which may be attributable to patient attrition from the study. Long-term economic evaluation suggested NMS may deliver better patient outcomes and reduced overall healthcare costs than normal practice, but uncertainty around this finding is high. TRIAL REGISTRATION NUMBER: NCT01635361, ISRCTN23560818, ISRCTN23560818, UKCRN12494.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.